Cardinal Health (CAH) has been in a spotlight recently with mixed developments. Despite a setback from losing a contract with OptumRx, its valuation seems to be high which makes the name not very attractive, and the company has also faced a warning from the US FDA for marketing unapproved devices. Positive elements include surpassing analyst EPS forecasts and raising FY24 guidance, increasing its quarterly dividend, and continued business growth. Furthermore, the company has shown a strong momentum and potential for the long-term. The acquisition of Specialty Networks and its PP Analytics platform for $1.2B is deepening its focus on specialty pharma. Its position as a major player in the growing home-based care space is also being acknowledged. Despite occasional dips, overall, the company has shown improvement in its technical strength and a rising price performance. Large institutions heavily dominate Cardinal Health with 89% of institutional ownership.
Cardinal Health CAH News Analytics from Tue, 15 Aug 2023 07:00:00 GMT to Sun, 26 May 2024 15:26:58 GMT -
Rating 1
- Innovation 6
- Information 7
- Rumor -5
